TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Significant Drop in Short Interest

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 24,700 shares, a decline of 85.2% from the June 30th total of 167,200 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average daily trading volume, of 1,400,000 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of TransCode Therapeutics in a research note on Wednesday, May 29th.

Institutional Investors Weigh In On TransCode Therapeutics

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC purchased a new position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics as of its most recent SEC filing.

TransCode Therapeutics Stock Performance

Shares of NASDAQ RNAZ remained flat at $0.30 during trading hours on Thursday. The company had a trading volume of 1,270,871 shares, compared to its average volume of 981,876. The company’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.06. TransCode Therapeutics has a 1-year low of $0.29 and a 1-year high of $128.00.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.05. On average, analysts predict that TransCode Therapeutics will post -1.98 EPS for the current year.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.